Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287399 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Ascletis Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT05287399 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Ascletis Pharmaceuticals Co.. The registered enrollment target is 18 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT05287399, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Ascletis Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.
Conditions Studied
Interventions
- DRUG ASC61 200 mg 1
- DRUG ASC61 200 mg 2
- DRUG ASC61 300 mg
- DRUG ASC61 400 mg
- DRUG ASC61 600 mg
Study Locations (4)
California
- California Cancer Associates for Research & Excellence (cCARE) - Encinitas
- California Cancer Associates for Research & Excellence (cCARE) - Fresno
- California Cancer Associates for Research & Excellence (cCARE) - San Marcos
Nebraska
- Nebraska Cancer Specialists - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287399
The ClinicalTrials.gov registry entry for NCT05287399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (91% lower). The listed sponsor is Ascletis Pharmaceuticals Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which ASC61 200 mg 1 is the first listed.
NCT05287399 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT05287399 about?
NCT05287399 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors". This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanc...
What is the current status of trial NCT05287399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-08-02. Estimated completion is 2025-01-17.
What conditions does trial NCT05287399 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05287399?
The interventions under investigation include: ASC61 200 mg 1 (DRUG), ASC61 200 mg 2 (DRUG), ASC61 300 mg (DRUG), ASC61 400 mg (DRUG), ASC61 600 mg (DRUG).
Who is sponsoring clinical trial NCT05287399?
This trial is sponsored by Ascletis Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287399 being conducted?
This trial has 4 study locations across California, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.